content top

Efficacy of Ocriplasmin in Patients with Vitreomacular Traction

Background/Advantages: Since May 2013 ocriplasmin (Jetrea, Alcon) has been available on the German market for the treatment of vitreomacular traction (VMT) including when associated with a macular hole of less than or equal to 400 microns. The main aim of this study was to treat a more homogenous group of patients with specific baseline characteristics with ocriplasmin, and to compare the results with those of previous trials. Patient...

Read More

A Single Injection of Ocriplasmin for the Treatment of Symptomatic Vitreomacular Adhesion (sVMA): Results of the Phase III MIVI-TRUST Program

Peter Stalmans for the MIVI-TRUST Study Group (Leuven, Belgium) Purpose: Symptomatic vitreomacular adhesion (sVMA) is implicated in the pathobiology of retinal disorders including vitreomacular traction syndrome and macular hole, and is associated with more severe disease in other conditions such as diabetic retinopathy, DME, and AMD. The MIVI-TRUST program is composed of two Phase III trials evaluating ocriplasmin for the treatment of sVMA...

Read More

The Use of “Vitrenal” for Vitreosyneresis in Experiment

Authors: T.K. Botabekova, G.K. Zhurgymbayeva, Zh. B. Meermanova, E. G. Kanafianova, D.L. Dauletbekov. Almaty, Kazakhstan Advantages / Purpose: To experimentally substantiate the use of «Vitrenal» for Vitreosyneresis. Methods: The properties of «Vitrenal» were studied on 12 rabbits. The animals were divided in 3 groups with 4 rabbits. In the group 1 and 2, Vitrenal 0.5% and 1.0% (solution of polymer chitozan) was injected in the...

Read More

The MIVI III (Microplasmin for Vitreous Injection III) Trial

http://www.evrs.eu/medias/2008/congress/The-MIVI-III-(Microplasmin-for-Vitreous-Injection-III)-Trial.flv Thierry Verstraeten, MD on behalf of the MIVI III Investigators Advantages: Previous clinical evaluation has shown microplasmin to be generally well tolerated and able to induce PVD as well as nonsurgical traction release and in some cases nonsurgical macular hole closure. Methods: The purpose of this trial is to evaluate the safety...

Read More

Pharmacological Release of Vitreomacular Traction Using

http://www.evrs.eu/medias/2008/congress/Pharmacological-Release-of-Vitreomacular-Traction-Using.flv Peter Stalmans, Marc De Smet, Christophe Delaey Advantages: Vitreomacular traction (VMT) with decreased visual function is a common indication to perform a vitrectomy. Pharmacologic release of the traction from the fovea may omit the need to perform a vitrectomy in these cases. Methods: Patients were included in a phase II randomized...

Read More

Posterior Vitreous Detachment Induced by Plasmin Enzyme During Surgery

Claudio Azzolini, MD, Matteo Prati, MD, Marco Codenotti, MD, Gisella Maestranzi, MD, Armando D’Angelo, Patrizia Della Valle Purpose: To evaluate the efficacy of autologous plasmin enzyme in inducing a posterior vitreous detachment (PVD). Methods: 30 eyes of 29 patients (group 1) with different vitreoretinal diseases were considered. All eyes received immediately before vitreoretinal surgery an intravitreal injection of different...

Read More
content top